Title
Category
Credits
Event date
Cost
Part 2: Importance and Implications of Biomarkers in Diagnosis and Modern Treatment of Alzheimer’s Disease
$0.00
Not only are cases of mild cognitive impairment (MCI) often not diagnosed, but more than 50% of these patients are misdiagnosed. One contributor to these observations is the fact that with biomarker assessments historically restricted (even in formal guidelines) to research, clinicians commonly rely on clinical scales, often with poor sensitivity to early stages, to generate suspicion of Alzheimer’s disease (AD).
Part 3: Evolving Roles in Alzheimer’s Disease Management: Team-Based Care in the Modern Age of Disease-Modifying Therapy
$0.00
Due to the growing complexity in the management of Alzheimer’s disease (AD), patient care falls under a wide umbrella of clinical team members across specialties, increasing the complexity of disease management. As successful team-based care was a challenge even prior to the introduction of biomarkers and disease-modifying therapies to clinical practice, individual team member recognition of and proficiency in their changing roles and responsibilities is critical to ensure new strategies are executed effectively.
Battle of the Biomarkers: Assessing Key Factors in Prognosis, Monitoring, and Therapeutic Decision-Making for Disease Worsening in Multiple Sclerosis
$0.00
OverviewOver the past several years, the image of MS has been changing from distinct categories of disease to a complicated spectrum of interwoven pathologies. As this knowledge evolves, so do approaches to prognosticating, monitoring, and responding to disease. With many markers of progression still under investigation and therefore not included in modern guidelines, MS clinicians are left on their own to decide which factors should hold the most weight in influencing clinical decisions.
A Deeper Look at Neuromyelitis Optica Spectrum Disorder: A Glimpse Onto the Clinic Floor with Specialists
$0.00
OverviewThough neuromyelitis optica spectrum disorder (NMOSD) has had a specific lab marker (AQP4 antibody) for many years, its relapsing nature and overlapping syndromes still causes it to be confused with multiple conditions such as multiple sclerosis (MS), leading to inappropriate and even harmful treatment. The emergence of similarly presenting MOG antibody disease as its own entity has further complicated the picture. Thankfully, FDA-approved targeted therapies have recently become available to treat NMOSD.
Stronger Together: Leveraging Evidence-Based Patient Collaboration and Treatment Strategies to Streamline Success in Multiple Sclerosis
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
$0.00
Program DescriptionWith the variety of possible risk factors, presentations, impacts, and preferences among individual patients with multiple sclerosis (MS), it has been well-established that every case of MS is unique. It is perhaps because of this that a collaborative, shared decision-making (SDM) approach has emerged as the preferred model of clinical care. However, in an age of over 20 FDA-approved disease modifying therapies (DMTs) and continuously evolving strategies for monitoring therapeutic response, the scope of shared clinical decisions is increasingly broad.
Unlocking the Alzheimer’s Brain: How Radiological Tools and Biomarkers Hold the Key to Early Diagnosis and Decision-Making
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
$0.00
Program DescriptionThe age of disease-modifying therapy in Alzheimer’s disease (AD) is now a reality with one amyloid beta targeting therapy (ATT) approved and another under regulatory review. Both agents require early diagnosis and therapeutic initiation to exert their effects. Not only is imaging a key component for the diagnosis of AD and to determine ATT eligibility, but all ATTs have the potential for unique adverse effects called amyloid-related imaging abnormalities (ARIA), necessitating frequent MRI monitoring and evaluation.
The Frontline of Alzheimer's Care: Addressing Real Questions from Clinicians in the New Dawn of Disease-Modifying Therapy
$0.00
Due to the unique educational design of this course, the content must be viewed and completed on the ReachMD platform.Program DescriptionAlzheimer’s Disease (AD) has historically been a condition associated with more questions than answers.
On the Clinic Floor: Addressing the Most Critical Questions of Frontline Clinicians in Multiple Sclerosis Management
$0.00
Due to the unique educational design of this course, the content must be viewed and completed on the ReachMD platform.Program DescriptionThe field of multiple sclerosis (MS) is evolving at a rapid pace from disease modifying therapies (DMTs) to diagnostic/monitoring tools to fundamental principles that shape how clinicians think about the disease.
Following a Moving Target: Current and Emerging Strategies for the Prevention and Management of COVID-19 in Patients with Multiple Sclerosis
04/30/2024
$0.00
Program DescriptionAs our understanding of COVID-19 advances, so too does our understanding of its impact on multiple sclerosis (MS). Drs.
The Hidden Side of Multiple Sclerosis: Harnessing Key Pathologies to Improve Outcomes Across the Multiple Sclerosis Spectrum
05/30/2024
$0.00
Program DescriptionThe understanding of MS pathophysiology has rapidly advanced in recent years. Not only does this immense progress bring clarity to once poorly understood processes such as the drivers of progressive disease, but it has also prompted reevaluation of concepts that were once considered understood.

Pages